

References

I-122

1. Kalbitor (ecallantide) injection, for subcutaneous use [package insert]. Dyax Corp. Burlington, MA. Revised 03/2015.
2. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Ecallantide. 2020.
3. Micromedex®Solutions Compendia. 2020. Ecallantide.
4. Ecallantide In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. 2020.
5. Firazyr (icatibant) injection, for subcutaneous use [package insert]. Takeda Pharmaceuticals America, Inc. Lexington, MA. Revised 08/2020.
6. Ruconest (C1 Esterase inhibitor, recombinant) for intravenous use [package insert]. Pharming Healthcare Inc. Bridgewater, NJ. Revised 12/2019.
7. Berinert (C1 Esterase inhibitor, human) for intravenous use [package insert]. CSL Behring LLC. Kankakee, IL. Revised 04/2019.
8. Cinryze (C1 esterase inhibitor, human) for intravenous use [package insert]. Shire ViroPharma Inc. Lexington, MA. Revised 06/2018.
9. Henao M, Kraschnewski J, Kelbel T, et Diagnosis and screening of patients with hereditary angioedema in primary care. *Ther Clin Risk Manag.* 2016;12:701-711.
10. Bernstein J, Riedl M, Zacek L. Facilitating home-based treatment of hereditary angioedema. *Allergy Asthma Proc.* 2015;36:92-99.
11. S. Hereditary Angioedema Association. (haea). US hereditary angioedema association medical advisory board 2013 recommendations for the management of hereditary angioedema due to c1 inhibitor deficiency. Accessed April 13, 2017.
12. Henry, H, Kaliner M. Angioedema Treatment & Management. *Medscape*. Last updated April 12, Histaminergic Angioedema (IH-AAE).
13. Bernstein JA, Riedl M, Zacek Facilitating home-based treatment of hereditary angioedema. *Allergy Asthma Proc.* 2015;92-99.
14. Polinski JM, Kowal MK, Gagnon M, et Home infusion: safe clinically effective, patient preferred, and cost saving. Healthcare. 2016.
15. ASHP Guidelines on Home Infusion Pharmacy Services,
16. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
17. Micromedex®Solutions Compendia. 2020. C1 Esterase Inhibitor, recombinant.
18. Micromedex®Solutions Compendia. 2020. C1 Esterase Inhibitor, human.
19. ®Solutions Compendia. 2020. Icatibant.

20. Icatibant In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. 2020.
21. MICROMEDEX®SOLUTIONS 2017. Ecallantide.
22. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. C1 Esterase Inhibitor. 2020.
23. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. C1 Esterase Inhibitor, human. 2020.
24. Takhzyro (lanadelumab) injection, for subcutaneous use [package insert]. Dyax Corp. Lexington, MA. Revised 11/2018.
25. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Lanadelumab. 2020.
26. Micromedex®Solutions Compendia. 2020. Lanadelumab.
27. Hayes Inc. Prognosis Overview. Takhzyro (lanadelumab-flyo). December 2018. Accessed February 27, 2019.
28. Lanadelumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. 2020.
29. Haegarda (C1 Esterase inhibitor, human) for subcutaneous injection [package insert]. CSL Behring LLC. Kankakee, IL. Revised 09/2020.
30. Li JJ, Mycroft S, Christiansen S, Wood DN, Feuersenger H, Pawaskar D, et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. *Allergy and Asthma*. 2018;39(5):365-370.
31. Busse PJ, Farkas H, Baneril A, et al. Lanadelumab for the prophylactic treatment of hereditary angioedema with C1 inhibitor deficiency: a review of preclinical and phase I studies. *BioDrugs*. 2019;33(1):33-43.
32. Levy D, Craig T, Keith PK, Krishnarajah G, Beckerman R, Prusty S. Co-occurrence between C1 esterase inhibitor deficiency and autoimmune disease: a systematic literature review. *Allergy, Asthma & Clinical Immunology*. 2020;16(1):1-8.
33. Levy DS, Farkas H, Riedl MA, et al. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. *Allergy, Asthma & Clinical Immunology*. 2020;16(1):1-9.
34. Aygören PE, Soteris DF, Nieto MSA, et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. *Pediatric Allergy & Immunology*. 2019;30(5):553-561.
35. [C1 Esterase Inhibitor, recombinant] In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. 2020.

36. [C1 Esterase Inhibitor, human] In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. 2020.
37. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Icatibant. 2020.